{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-000450","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.205647+00:00","generated_at":"2026-06-20T19:44:02.696843+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zai Lab partner Novocure's LUNAR study meets primary overall survival endpoint in stage 4 NSCLC","bullets":["LUNAR study showed statistically significant and clinically meaningful improvement in overall survival vs standard therapies alone.","TTFields + immune checkpoint inhibitors demonstrated significant OS benefit; positive trend with TTFields + docetaxel.","Zai Lab has exclusive license to develop and commercialize TTFields in mainland China, Hong Kong, Macau, and Taiwan.","Novocure plans to file PMA with FDA and CE Mark in EU in H2 2023; full results at future medical congress."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-000450","json":"https://secwatch.observer/filing/0001628280-23-000450.json","markdown":"https://secwatch.observer/filing/0001628280-23-000450.md","text":"https://secwatch.observer/filing/0001628280-23-000450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023000450/0001628280-23-000450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023000450/zlab-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:44:02.696843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}